Loading data for BIVI — first visit, this takes a few seconds.
BioVie Inc. (BIVI)
NasdaqCM: BIVI
· Real-Time Price · USD
2.00
-0.03 (-1.48%)
At close: Sep 04, 2026, 8:00 PM
2.00
-0.02%
After-hours: 7:58 PM
The price, the headline numbers and the latest news, in one place.
BioVie Inc. (BIVI) Stock Price, Analysis & Data
No data available
| Bid | 1.47 |
| Market Cap | 16.9M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.1M |
| 0.74 | |
| -3.05 | |
| n/a | |
| -3.51 | |
| P/B (ttm) | 1.47 |
| P/S (ttm) | 0.00 |
| Earnings Date | Aug 24, 2026 |
| Ask | 2.62 |
| Volume | 296,762 |
| Avg. Volume (20D) | 4,617,471 |
| Open | 2.04 |
| Previous Close | 2.03 |
| Day's Range | 1.96 - 2.08 |
| 52-Week Range | 0.82 - 3.79 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BIVI
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally adminis...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 18, 2020
Employees 13
Stock Exchange NasdaqCM
Ticker Symbol BIVI
Website https://bioviepharma.com
Financial Performance
In 2025, BioVie's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -17.54M, a decrease of -45.39%.
Financial StatementsEarnings Surprise
BioVie has released their quarterly earnings on Nov 10, 2025:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.98 misses estimates by -0.19, with 95.10% YoY growth.
BioVie Inc. is scheduled to release its earnings on Aug 24, 2026, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2